News & Updates

Show Multimedia Only

Old age, metastatic cancer predict cisplatin-induced nephrotoxicity

12 Nov 2020

Age >65 years and metastatic cancer are significantly associated with cisplatin-induced nephrotoxicities, a recent study has found. An association also exists between cumulative dose and nephrotoxicity or digestive toxicity.

Old age, metastatic cancer predict cisplatin-induced nephrotoxicity

12 Nov 2020

Pre-radiotherapy CT scan may help identify CVD risk in women with breast cancer

11 Nov 2020 by

The use of an algorithm to identify the presence of coronary artery calcifications (CAC) during radiotherapy-planning CT scans may help assess cardiovascular disease (CVD) risk in women with breast cancer, according to a study from the Netherlands.

Pre-radiotherapy CT scan may help identify CVD risk in women with breast cancer

11 Nov 2020

Anxiety high among oesophageal cancer patients

11 Nov 2020

Patients suffering from oesophageal cancer suffer from heightened levels of generalized anxiety disorder, reports a new study.

Anxiety high among oesophageal cancer patients

11 Nov 2020

Primary endocrine therapy vs surgery: Comparable survival in older Chinese breast cancer patients

10 Nov 2020 by

Primary endocrine therapy (ET) alone may be appropriate for treatment of frail elderly patients aged ≥70 years with limited life expectancy diagnosed with stage I–III oestrogen receptor (ER)–positive breast cancer (BC), whereas those with longer life expectancy may gain overall survival (OS) benefit from local operation, a matched case-control study by the University of Hong Kong (HKU) has shown.

Primary endocrine therapy vs surgery: Comparable survival in older Chinese breast cancer patients

10 Nov 2020

Frontline apatinib plus gefitinib improves survival in EGFR-mutant NSCLC

10 Nov 2020 by

A combined regimen of apatinib plus gefitinib as first-line treatment improves progression-free survival (PFS) vs placebo plus gefitinib in patients with advanced EGFR-mutant (EGFRm) non-squamous non-small-cell lung cancer (NSCLC), results of the phase III ACTIVE study have shown.

Frontline apatinib plus gefitinib improves survival in EGFR-mutant NSCLC

10 Nov 2020

LDH, MLR linked to prognosis in older patients with mCRC

10 Nov 2020

High lactate dehydrogenase (LDH) and monocyte-to-lymphocyte ratio (MLR) levels in the sera of older patients with metastatic colorectal cancer (mCRC) signal unfavourable disease prognosis, a recent study has found.

LDH, MLR linked to prognosis in older patients with mCRC

10 Nov 2020

First-line nivolumab-cabozantinib improves PFS, OS, ORR in advanced clear cell RCC

09 Nov 2020 by

The combination of nivolumab and cabozantinib in the first-line setting conferred greater survival outcomes and responses compared with sunitinib in patients with clear cell advanced renal cell carcinoma (RCC), results of the phase III CheckMate 9ER trial showed.

First-line nivolumab-cabozantinib improves PFS, OS, ORR in advanced clear cell RCC

09 Nov 2020

Dermatologists crucial to managing side effects of EGFR inhibitor for NSCLC

09 Nov 2020 by

The use of epidermal growth factor receptor (EGFR) inhibitors for the treatment of nonsmall cell lung cancer (NSCLC) commonly triggers cutaneous side effects, which often leads to drug reductions or discontinuation, reports a new study at the recently concluded 2020 Virtual Congress of the European Academy of Dermatology and Venereology (EADV 2020).

Dermatologists crucial to managing side effects of EGFR inhibitor for NSCLC

09 Nov 2020

Pancreatic cancer incidence and mortality on the rise globally

09 Nov 2020 by

The incidence and mortality of pancreatic cancer are on the rise globally, particularly among women and individuals ≥50 years of age, but an increasing trend is also found in younger individuals in some countries.

Pancreatic cancer incidence and mortality on the rise globally

09 Nov 2020

Circulating tumour DNA linked to worse outcomes in melanoma

07 Nov 2020

Melanoma patients with detectable levels of circulating tumour DNA carrying mutations in the BRAF, NRAS, and TERT genes tend to have unfavourable disease outcomes, a recent study has found.

Circulating tumour DNA linked to worse outcomes in melanoma

07 Nov 2020

News & Updates

Filter by Specialty:

Specialty:

Old age, metastatic cancer predict cisplatin-induced nephrotoxicity

Old age, metastatic cancer predict cisplatin-induced nephrotoxicity

Pre-radiotherapy CT scan may help identify CVD risk in women with breast cancer

Pre-radiotherapy CT scan may help identify CVD risk in women with breast cancer

Anxiety high among oesophageal cancer patients

Anxiety high among oesophageal cancer patients

Primary endocrine therapy vs surgery: Comparable survival in older Chinese breast cancer patients

Primary endocrine therapy vs surgery: Comparable survival in older Chinese breast cancer patients

Frontline apatinib plus gefitinib improves survival in EGFR-mutant NSCLC

Frontline apatinib plus gefitinib improves survival in EGFR-mutant NSCLC

LDH, MLR linked to prognosis in older patients with mCRC

LDH, MLR linked to prognosis in older patients with mCRC

First-line nivolumab-cabozantinib improves PFS, OS, ORR in advanced clear cell RCC

First-line nivolumab-cabozantinib improves PFS, OS, ORR in advanced clear cell RCC

Dermatologists crucial to managing side effects of EGFR inhibitor for NSCLC

Dermatologists crucial to managing side effects of EGFR inhibitor for NSCLC

Pancreatic cancer incidence and mortality on the rise globally

Pancreatic cancer incidence and mortality on the rise globally

Circulating tumour DNA linked to worse outcomes in melanoma

Circulating tumour DNA linked to worse outcomes in melanoma